IL6R
ENSG00000160712
Target class
Secreted protein
Chromosome
1
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- IL6R
- Gene name
- Interleukin 6 receptor
- Gene symbol
- IL6R
- Protein name
- Interleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126) [Cleaved into: Soluble interleukin-6 receptor subunit alpha (sIL6R)]
- CD126
- IL-6R
- IL-1Ra
- IL6RA
- gp80
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Immunoglobulin like domain containing|Interleukin receptors
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 67.24
- Tissue specificity (Gini)
- 0.466
- Tissue specificity (tau)
- 0.818
- KEGG gene identifiers
- hsa:3570
- Protein interaction confidence
- 0.822126
- Protein interaction partners
- 95
- R-HSA-1059683
- R-HSA-110056
- R-HSA-112411
- R-HSA-6785807
- R-HSA-9616222
- R-HSA-9679191
- R-HSA-9958825
- End position
- 154469450
- Start position
- 154405193
- Chromosome
- 1
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 2]: Secreted .
- SUBCELLULAR LOCATION: [Soluble interleukin-6 receptor subunit alpha]: Secreted .
Publication evidence
- PubMed 28060820
- Tissue specificity (tau)
- 0.818325
- Expression inequality (Gini)
- 0.465862
Expression in transcripts per million
- Muscle - Skeletal
- 67.24
- Whole Blood
- 52.69
- Liver
- 38.03
- Lung
- 29.45
- Esophagus - Muscularis
- 27.04
Expression in transcripts per million
- Muscle - Skeletal67.24
- Whole Blood52.69
- Liver38.03
- Lung29.45
- Esophagus - Muscularis27.04
- Fallopian Tube25.91
- Colon - Sigmoid25.73
- Esophagus - Gastroesophageal Junction25.38
- Spleen24
- Uterus23.29
- Small Intestine - Terminal Ileum22.03
- Colon - Transverse19.86
- Nerve - Tibial18.59
- Cervix - Endocervix18.16
- Artery - Tibial17.44
- Ovary16.13
- Adipose - Subcutaneous16.11
- Adipose - Visceral (Omentum)15.19
- Cervix - Ectocervix14.4
- Artery - Coronary13.62
- Pituitary13.57
- Bladder12.16
- Prostate11.66
- Breast - Mammary Tissue11.41
- Vagina11.1
And 29 more, listed on the interactive page.
- GO:0002384
- GO:0002548
- GO:0002690
- GO:0006953
- GO:0008284
- GO:0010573
- GO:0019221
- GO:0031018
- GO:0032722
- GO:0032755
- GO:0034097
- GO:0045669
- GO:0048661
- GO:0050829
- GO:0070102
- GO:0070120
- GO:0072126
- GO:0097191
- GO:0097696
- GO:0005576
- GO:0005886
- GO:0005896
- GO:0016324
- GO:0070110
- GO:0004897
- GO:0004915
- GO:0005138
- GO:0005515
- GO:0019899
- GO:0019981
- GO:0042803
- GO:0070119
regulation of transcription factor activity
- cell-based: LTEA_HepaRG_IL6Ris one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.
- cell-based: LTEA_HepaRG_IL6Ris one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.
Biological samples
- HepaRG, cell line
Evidence source
Related records
Trials (607)
- "Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
- A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19
- A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
- A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
- A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
- A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
- A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
- A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
- A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
- A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
- A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
- A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Drugs (5)
- Levilimab Interleukin-6 receptor alpha subunit inhibitor
- Sarilumab Interleukin-6 receptor alpha subunit antagonist
- Satralizumab IL6Ralpha/GP130 antagonist
- Tocilizumab Interleukin-6 receptor alpha subunit inhibitor
- Vobarilizumab Interleukin-6 receptor alpha subunit inhibitor